Altimmune (ALT) Change in Accured Expenses (2010 - 2026)
Altimmune (ALT) reported Change in Accured Expenses of -$2.5 million for Q1 2026, down 46.73% year-over-year from -$4.7 million in Q1 2025, and down 157.3% on a QoQ basis from $4.4 million in Q4 2025.
Altimmune (ALT) has 17 years of Change in Accured Expenses data on file, last reported at -$2.5 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 46.73% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 68.96% YoY) and the FY2025 annual result came in at $2.4 million, up 2233.04% from the prior year.
- Change in Accured Expenses eased to -$2.5 million in Q1 2026 per ALT's latest filing, from $4.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.4 million in Q3 2022 and bottomed at -$4.7 million in Q3 2024.
- The 5-year median for Change in Accured Expenses is -$365000.0 (2025), against an average of $193764.7.
- Peak annual rise in Change in Accured Expenses reached 338.47% in 2024, while the deepest fall reached 392.0% in 2024.
- Tracing ALT's Change in Accured Expenses over 5 years: stood at -$2.2 million in 2022, then surged by 165.82% to $1.4 million in 2023, then jumped by 66.55% to $2.4 million in 2024, then jumped by 83.59% to $4.4 million in 2025, then tumbled by 157.3% to -$2.5 million in 2026.
- Per Business Quant, the three latest ALT Change in Accured Expenses figures stand at -$2.5 million (Q1 2026), $4.4 million (Q4 2025), and $102000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | -2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.49 Mn |
| Mar 31, 2026 | -2.49 Mn |
| Dec 31, 2025 | 4.35 Mn |
| Dec 31, 2025 | 4.35 Mn |
| Sep 30, 2025 | 102,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | -365,000.00 |
| Jun 30, 2025 | -365,000.00 |
| Mar 31, 2025 | -1.70 Mn |
| Mar 31, 2025 | -1.70 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Sep 30, 2024 | -4.74 Mn |
| Sep 30, 2024 | -4.74 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | -2.76 Mn |
| Mar 31, 2024 | -2.76 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | -2.10 Mn |
| Jun 30, 2023 | -2.10 Mn |
| Mar 31, 2023 | -2.83 Mn |
| Mar 31, 2023 | -2.83 Mn |
| Dec 31, 2022 | -2.16 Mn |
| Dec 31, 2022 | -2.16 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | -1.54 Mn |
| Jun 30, 2022 | -1.54 Mn |
| Mar 31, 2022 | 2.66 Mn |
| Mar 31, 2022 | 2.66 Mn |
| Dec 31, 2021 | -9.22 Mn |
| Dec 31, 2021 | -9.22 Mn |
| Sep 30, 2021 | 10.97 Mn |
| Sep 30, 2021 | 10.97 Mn |
| Jun 30, 2021 | -1.86 Mn |
| Jun 30, 2021 | -1.86 Mn |
| Mar 31, 2021 | -2.19 Mn |
| Mar 31, 2021 | -2.19 Mn |
| Dec 31, 2020 | 5.79 Mn |
| Dec 31, 2020 | 5.79 Mn |
| Sep 30, 2020 | 1.17 Mn |
| Sep 30, 2020 | 1.17 Mn |
| Jun 30, 2020 | -1.09 Mn |
| Jun 30, 2020 | -1.09 Mn |
| Mar 31, 2020 | 1.11 Mn |
| Mar 31, 2020 | 1.11 Mn |
| Dec 31, 2019 | 1.49 Mn |
| Dec 31, 2019 | 1.49 Mn |
| Sep 30, 2019 | -1.09 Mn |
| Sep 30, 2019 | -1.09 Mn |
| Jun 30, 2019 | -481,515.00 |
| Jun 30, 2019 | -481,515.00 |
| Mar 31, 2019 | -699,942.00 |
| Mar 31, 2019 | -699,942.00 |
| Dec 31, 2018 | -1.68 Mn |
| Dec 31, 2018 | -1.68 Mn |
| Sep 30, 2018 | 534,881.00 |
| Sep 30, 2018 | 534,881.00 |
| Jun 30, 2018 | 443,481.00 |
| Jun 30, 2018 | 443,481.00 |
| Mar 31, 2018 | 716,934.00 |
| Mar 31, 2018 | 716,934.00 |
| Dec 31, 2017 | -329,971.00 |
| Dec 31, 2017 | -329,971.00 |
| Sep 30, 2017 | -751,329.00 |
| Sep 30, 2017 | -751,329.00 |
| Jun 30, 2017 | 1.45 Mn |
| Jun 30, 2017 | 1.45 Mn |
| Mar 31, 2017 | -733,736.00 |
| Mar 31, 2017 | -733,736.00 |
| Dec 31, 2016 | 510,894.00 |
| Dec 31, 2016 | 510,894.00 |
| Sep 30, 2016 | 520,807.00 |
| Sep 30, 2016 | 520,807.00 |
| Jun 30, 2016 | -906,702.00 |
| Jun 30, 2016 | -906,702.00 |
| Mar 31, 2016 | 466,563.00 |
| Mar 31, 2016 | 466,563.00 |
| Dec 31, 2015 | -204,256.00 |
| Dec 31, 2015 | -204,256.00 |
| Sep 30, 2015 | -497,795.00 |
| Sep 30, 2015 | -497,795.00 |
| Jun 30, 2015 | 417,047.00 |
| Jun 30, 2015 | 417,047.00 |
| Mar 31, 2015 | 230,186.00 |
| Mar 31, 2015 | 230,186.00 |
| Dec 31, 2014 | -1.32 Mn |
| Dec 31, 2014 | -1.32 Mn |
| Sep 30, 2014 | 1.06 Mn |
| Sep 30, 2014 | 1.06 Mn |
| Jun 30, 2014 | -563,225.00 |
| Jun 30, 2014 | -563,225.00 |
| Mar 31, 2014 | -1.27 Mn |
| Mar 31, 2014 | -1.27 Mn |
| Dec 31, 2013 | 569,615.00 |
| Dec 31, 2013 | 569,615.00 |
| Sep 30, 2013 | 570,087.00 |
| Sep 30, 2013 | 570,087.00 |
| Jun 30, 2013 | -1.32 Mn |
| Jun 30, 2013 | -1.32 Mn |
| Mar 31, 2013 | 950,800.00 |
| Mar 31, 2013 | 950,800.00 |
| Dec 31, 2012 | -873,260.00 |
| Dec 31, 2012 | -873,260.00 |
| Sep 30, 2012 | 47,096.00 |
| Sep 30, 2012 | 47,096.00 |
| Jun 30, 2012 | 276,750.00 |
| Jun 30, 2012 | 276,750.00 |
| Mar 31, 2012 | 131,338.00 |
| Mar 31, 2012 | 131,338.00 |
| Dec 31, 2011 | -596,195.00 |
| Dec 31, 2011 | -596,195.00 |
| Sep 30, 2011 | -199,939.00 |
| Sep 30, 2011 | -199,939.00 |
| Jun 30, 2011 | 668,565.00 |
| Jun 30, 2011 | 668,565.00 |
| Mar 31, 2011 | -264,335.00 |
| Mar 31, 2011 | -264,335.00 |
| Dec 31, 2010 | -224,123.00 |
| Dec 31, 2010 | -224,123.00 |
| Sep 30, 2010 | -1.06 Mn |
| Sep 30, 2010 | -1.06 Mn |